- Home
- VALN vs MGTX Comparison
VALN vs MGTX Comparison
Compare VALN & MGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | VALN | MGTX |
|---|---|---|
| Founded | 2012 | 2015 |
| Country | France | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 820.0M | 744.9M |
| IPO Year | 2021 | N/A |
Fundamental Metrics
Financial Performance| Metric | VALN | MGTX |
|---|---|---|
| Price | $8.69 | $8.87 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 6 |
| Target Price | $15.75 | ★ $23.83 |
| AVG Volume (30 Days) | 20.4K | ★ 625.1K |
| Earning Date | 11-20-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $211,089,992.00 | $27,417,000.00 |
| Revenue This Year | $5.08 | N/A |
| Revenue Next Year | $12.53 | $619.95 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | 13.48 | ★ 96.83 |
| 52 Week Low | $3.62 | $4.55 |
| 52 Week High | $12.25 | $9.73 |
Technical Indicators
Market Signals| Indicator | VALN | MGTX |
|---|---|---|
| Relative Strength Index (RSI) | 44.50 | 60.33 |
| Support Level | $8.69 | $8.25 |
| Resistance Level | $9.10 | $9.50 |
| Average True Range (ATR) | 0.28 | 0.52 |
| MACD | 0.02 | 0.11 |
| Stochastic Oscillator | 14.15 | 70.24 |
Price Performance
Historical ComparisonAbout VALN Valneva SE
Valneva SE is a vaccine company focused on developing life-saving vaccines. Its portfolio includes three vaccines for travelers. The segments of the group are Commercialized vaccines which relate to marketed vaccines, the group's vaccines IXIARO/JESPECT, DUKORAL, IXCHIQ; Covid includes development, manufacturing, & distribution related to the COVID-19 vaccine, Vaccine candidates which relate to research and development programs to generate new approvable products to generate future cash flows from product sales through partnering with pharmaceutical companies; & Technologies and services which relate to services and inventions at a commercialization stage. The company generates majority of its revenue from product sales.
About MGTX MeiraGTx Holdings plc
MeiraGTx Holdings PLC is a clinical-stage gene therapy company. It focuses on the eye, salivary gland, and central nervous system disorders. The company's pipeline products include AAV-CNGB3, AAV-CNGA3 and AAV-RPGR, and others. Geographically, it operates in the United States, the United Kingdom, and European Union.